@uget1shot I have SIBO and severe gut dysbiosis. Negative active c diff but high levels of c diff a and b on my GI MAP. Although the GI MAP does NOT diagnose an acute infection, it does give pointers to what’s happening in your colon and my GI MAP I had done prior to COVID years ago, showed no c diff a toxin and b was a lot lower.
FMT is officially approved for c diff infections that are not responding to multiple rounds of vancomycin and the like.
Rifaximin is prescribed for SIBO. However, if you read Dr Pimentel’s research, Rifaximin has also been used for IBS, and then there are studies on it being tried with ulcerative colitis.
I have not been diagnosed with UC either.
However, Rifaximin has clinically shown to be helping me so my GI has been prescribing. Also Rifaximin has been used daily long term for hepatic encephalopathy (which has shown good long term results and safety).
Rifaximin mainly targets gram negative, leaving majority of biome alone. It also helps with detoxification of over growth and with inflammation. Hence, knocks down the overburden of toxins that build up in my system that is already taxed from LC.
It basically keeps things at bay to allow my body to heal. And it is!
My next trial is going to be Pridgin’s protocol of Valacyclovir and Paxlovid.
@repl So interesting! I was prescribed Rifaximin in 2022 for methane-dominant SIBO and it helped. I had tried the herbal route (using the gold standard proved out by a Johns Hopkins study to be equal but with less risk of rebound than with Rifaximin), but it didn't work for me. With this new perspective on Rifaximin, I now wonder if the so-called rebound effect with Rifaximin isn't because the drug fails but because it's only able to treat one condition with a 2-week course, and the remaining issue is one of IBS vs SIBO? My SIBO did clear up wonderfully with the Rifaximin. But what my doctors now believe to be IBS-C is worsening. I'll research the names you've provided, to selectively share with my new GI doc. Many thanks!!